India markets open in 5 hours 36 minutes
  • BSE SENSEX

    47,949.42
    -882.61 (-1.81%)
     
  • Nifty 50

    14,359.45
    -258.40 (-1.77%)
     
  • Dow

    34,077.63
    -123.04 (-0.36%)
     
  • Nasdaq

    13,914.77
    -137.58 (-0.98%)
     
  • BTC-INR

    4,201,661.00
    -1,979.50 (-0.05%)
     
  • CMC Crypto 200

    1,273.66
    -25.30 (-1.95%)
     
  • Hang Seng

    29,106.15
    +136.44 (+0.47%)
     
  • Nikkei

    29,685.37
    +2.00 (+0.01%)
     
  • EUR/INR

    90.1026
    +0.8298 (+0.93%)
     
  • GBP/INR

    104.6889
    +1.6738 (+1.62%)
     
  • AED/INR

    20.3340
    +0.1010 (+0.50%)
     
  • INR/JPY

    1.4422
    -0.0155 (-1.06%)
     
  • SGD/INR

    56.2870
    +0.4520 (+0.81%)
     

Affimed to Report Full Year 2020 Financial Results & Corporate Update on April 15, 2021

Affimed N.V.
·2-min read

Heidelberg, Germany, April 8, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2020 results and corporate update on Thursday, April 15, 2021. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time.

The conference call will be available via phone and webcast. To access the call, please dial +1-646-741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference conference ID 4271307 approximately 15 minutes prior to the call.

To access the live audio webcast of the conference call please visit the “Investors” section of the company’s website at https://www.affimed.com/investors/webcasts_cp/. A replay of the call will be archived on the Affimed website for 30 days after the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact

Alex Fudukidis
Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel: +1 (917) 436-8102